Advertisement
Advertisement
U.S. Markets open in 5 hrs 5 mins
Advertisement
Advertisement
Advertisement
Advertisement

Enveric Biosciences, Inc. (ENVB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.60-0.09 (-1.35%)
At close: 04:00PM EDT
6.55 -0.05 (-0.76%)
After hours: 07:53PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.69
Open6.71
Bid0.00 x 2900
Ask0.00 x 1000
Day's Range6.45 - 6.89
52 Week Range5.90 - 187.00
Volume107,501
Avg. Volume276,242
Market Cap207.132M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.67
Earnings DateNov 23, 2021 - Nov 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 23, 2008
1y Target Est32.50
  • Business Wire

    Enveric Biosciences Appoints New Independent Directors

    CAMBRIDGE, Mass., July 27, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors.

  • Business Wire

    Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

    CAMBRIDGE, Mass., July 26, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), priced at a premium to market under Nasdaq rules. In addition, the Company

  • Business Wire

    Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

    CAMBRIDGE, Mass., July 25, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has entered into a definitive agreement with an institutional investor for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq

Advertisement
Advertisement